Drug Discovery & DDS– category –
-
Ribo Life Science’s siRNA Therapeutic Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
Insight, China's Pharmaceutical Industry China Overview Ribo Life Science's siRNA therapeutic, vortosiran (BD4059), has received European Medicines Agency (EMA) approval for a clinical trial aimed at stroke prevention in atrial fibrillat... -
Daiichi Sankyo/AstraZeneca’s Datroway Receives US FDA Approval for First-Line Metastatic TNBC, EMA CHMP Gives Positive Opinion
Chemistry Today USA Overview Datroway (datopotamab deruxtecan), the TROP2-directed DXd ADC co-developed by Daiichi Sankyo and AstraZeneca, has received US FDA approval as a first-line treatment for unresectable or metastatic triple-negat... -
Tangram Therapeutics Advances TGM-312 to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial for MASH Treatment
BioSpace USA Overview Tangram Therapeutics announced the progression of TGM-312, a novel GalNAc-siRNA therapeutic for MASH (Metabolic Dysfunction-Associated Steatohepatitis), to patient cohorts in its Phase 1/2 RESTORE-MASH trial. TGM-31... -
Silence Therapeutics’ PV Drug Divesiran Achieves 88% Response Rate in Phase 2, Advances to Phase 3
Investing.com UK Overview Silence Therapeutics' GalNAc-siRNA therapeutic, divesiran, for polycythemia vera (PV) met its primary endpoint in the Phase 2 SANRECO study, demonstrating an impressive 88% response rate compared to 19% in the p... -
Gan & Lee’s First-in-Class AR PROTAC GLR2037 Receives NMPA Approval to Initiate Clinical Trials for Advanced Prostate Cancer
flcube.com China Overview Gan & Lee Pharmaceuticals announced that China's National Medical Products Administration (NMPA) has approved its first-in-class androgen receptor (AR) PROTAC, GLR2037, for clinical trials. This novel therap... -
First PROTAC Therapy for Breast Cancer Approved, Opening New Avenues for Precision Medicine in Advanced, Metastatic Disease with Specific Mutations
Nature Medicine Journal (Facebook) International Overview A PROTAC therapy for breast cancer has received medical approval, pioneering a new era of precision medicine for patients with advanced or metastatic breast cancer harboring speci... -
FDA Grants Breakthrough Therapy Designation to JBS-003 (18F-FMISO), First PET Tracer to Guide Radiation De-escalation in HPV-Positive Oropharyngeal Cancer
Cancer Network USA Overview The U.S. FDA has granted Breakthrough Therapy Designation to JBS-003 (18F-fluoromisonidazole [FMISO]), the first hypoxic PET tracer intended to identify tumor hypoxia and guide radiation therapy de-escalation ... -
Antibody-Drug Conjugates Prepared with Peptide Asparaginyl Ligase Enhance Uniformity and Antitumor Activity, Promising Pharmaceutical Applications
Molecular Cancer Therapeutics (AACR Journals) USA Overview Novel antibody-drug conjugates (ADCs) prepared using peptide asparaginyl ligase (PAL) demonstrated potent antitumor activity in both in vitro and in vivo models. This innovative ... -
First-in-Class Bispecific ADC BL-B01D1 Shows Antitumor Activity in Phase Ib Trial for Relapsed Extensive-Stage Small Cell Lung Cancer
ASCO Post USA Overview The first-in-class bispecific antibody-drug conjugate (ADC), izalontamab brengitecan (iza-bren, BL-B01D1), demonstrated promising antitumor activity in a Phase Ib study for relapsed extensive-stage small cell lung ... -
Novel TROP2-Targeting ADC, hIMB1636-LDP-AE, Demonstrates Potent Antitumor Efficacy and Anti-Cancer Stem Cell Activity in Breast and Lung Cancers
Medium (@wuhanmabnus) China Overview A novel antibody-drug conjugate (ADC), hIMB1636-LDP-AE, engineered through genetic and molecular recombination technologies, has demonstrated potent antitumor efficacy in both in vitro and in vivo mod...
